Low-dose lipopolysaccharide and fungal airway exposure were linked to persistent airway hyperresponsiveness despite glucocorticoid treatment in experimental models.
Long-term monitoring, trusted clinical relationships and no-cost treatment have improved outcomes, while mental health and sleep disorders continue to test the system.
From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.